Contact

Press Release

Press Release
Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa
SAN DIEGO (PRWEB) APRIL 15, 2019 Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that Allan Camaisa, Calidi Biotherapeutics CEO,…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Launches Scientific and Medical Advisory Board
SAN DIEGO, Jan. 3, 2019 /PRNewswire-PRWeb/ — Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding of a scientific…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO
SAN DIEGO, May 24, 2018 — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced a focused effort to advance its…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
SAN DIEGO, Nov. 6, 2018  — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses
SAN DIEGO, October 25, 2018 – Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a…
 
Read Morelaunch